Treatment with JG alone did not show an obvious immunity enhancement in tumor-bearing mice; however, the ratios of CD4+ and CD4+/CD8+ in the spleen improved significantly after administration of the PTX-JG combination when compared with the control group (p < 0.01, p < 0.05). This evidence concerns the gene CD4 and neoplasm.